You are here

Copaxone ®

Copaxone - as marketed by Teva Pharmaceuticals

The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis.  Copaxone® is licensed to Teva Pharmaceuticals Ltd.

  • Indicated for Multiple Sclerosis COPAXONE represents a new class of drugs for the treatment of the disease.
  • Copaxone is a synthetic copolymer acting as an immunomodulator.
  • 1971: First Patent filed by Yeda.
  • 1987: Licensed to Teva Pharmaceuticals Ltd.
  • 2007 Sales: $US 1.7 Billion Market Share: 34%
  • 2013 Sales: $US 4.3 Billion